IBI3016 vs Tonlamarsen

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Hypertension

Shared mechanism: Angiotensinogen (AGT) · full Hypertension pipeline

IBI3016

Developed by Suzhou Sanegene Bio and partners

Phase 2 in HypertensionRNAi (siRNA)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: January 2027 · NCT07838220 (registry estimate)

No aligned efficacy figure on record for this race.

Tonlamarsen

Developed by Kardigan under a licence from Ionis Pharmaceuticals

Phase 2 in Hypertensionantisense oligonucleotide
Partial signal

NCT06864104 · Phase 2 · completed

The study randomized 198 participants (206 entered the active run-in) to monthly tonlamarsen or to a single tonlamarsen dose followed by placebo, with participants, care providers, investigators and outcome assessors masked. It had two co-primary outcomes at week 20. Plasma angiotensinogen fell more with monthly dosing (P<0.0001), but office systolic blood pressure fell by 6.7 mm Hg in both groups (P=0.97). One co-primary outcome was met and one was missed, so the result is mixed. The figures are from the peer-reviewed publication (JACC 2026) and the registry's primary outcome list.

Next expected readout: December 2026 · NCT07511361 (registry estimate)

Reported efficacy

Co-primary: change from baseline to week 20 in plasma angiotensinogen and in office systolic blood pressure (between-group differences): Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. (mixed)

Result source: NCT06864104

Results for Hypertension

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIBI3016Tonlamarsen
Seated SBP, change—Not reported—Not reported
24-hour ambulatory SBP, change—Not reported—Not reported
Seated DBP, change—Not reported—Not reported

Seated SBP, change

IBI3016
—Not reported
Tonlamarsen
—Not reported

24-hour ambulatory SBP, change

IBI3016
—Not reported
Tonlamarsen
—Not reported

Seated DBP, change

IBI3016
—Not reported
Tonlamarsen
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

IBI3016: no structured comparison results are available for Hypertension.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Tonlamarsen
Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed. NCT06864104 · Phase 2 · design grade: moderate · publication or press release
(-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg) NCT05314439 · Phase 2 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: IBI3016's landscape · Tonlamarsen's landscape